CAPR (Capricor Therapeutics) Price-to-Operating-Cash-Flow : (As of Dec. 14, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Capricor Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-12-14), Capricor Therapeutics's share price is $13.26. Capricor Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.16. Hence, Capricor Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Capricor Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Capricor Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 116.97. The lowest was 7.37. And the median was 15.96.

CAPR's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 25.685
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Capricor Therapeutics's Cash Flow from Operations per share for the three months ended in Sep. 2024 was $-0.35. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.16.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -14.00% per year.

During the past 13 years, Capricor Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 73.70% per year. The lowest was -191.00% per year. And the median was 3.30% per year.

Capricor Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Capricor Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Price-to-Operating-Cash-Flow Chart

Capricor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

19.30

Capricor Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Capricor Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Capricor Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Price-to-Operating-Cash-Flow falls into.

Capricor Therapeutics Price-to-Operating-Cash-Flow Calculation

Capricor Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	13.26	/	-1.156
	=

Capricor Therapeutics's Share Price of today is $13.26.
Capricor Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Capricor Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

4LN2:Germany

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Executives

David B Musket	director	C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter	director	C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher	director	C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals	director	C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat	officer: CHIEF BUSINESS OFFICER	10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar	director	C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban	director, officer: CHIEF EXECUTIVE OFFICER	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr	director	C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney	officer: EVP, GENERAL COUNSEL	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann	officer: CHIEF FINANCIAL OFFICER	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo	director	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center	10 percent owner	8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A.	10 percent owner	2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022